These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12950426)

  • 21. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
    Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
    Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
    Tannenbaum H; Berenbaum F; Reginster JY; Zacher J; Robinson J; Poor G; Bliddal H; Uebelhart D; Adami S; Navarro F; Lee A; Moore A; Gimona A
    Ann Rheum Dis; 2004 Nov; 63(11):1419-26. PubMed ID: 15020310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
    Bombardier C; Laine L; Reicin A; Shapiro D; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ;
    N Engl J Med; 2000 Nov; 343(21):1520-8, 2 p following 1528. PubMed ID: 11087881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.
    Hawkey CJ; Laine L; Simon T; Quan H; Shingo S; Evans J;
    Gut; 2003 Jun; 52(6):820-6. PubMed ID: 12740337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
    Esser R; Berry C; Du Z; Dawson J; Fox A; Fujimoto RA; Haston W; Kimble EF; Koehler J; Peppard J; Quadros E; Quintavalla J; Toscano K; Urban L; van Duzer J; Zhang X; Zhou S; Marshall PJ
    Br J Pharmacol; 2005 Feb; 144(4):538-50. PubMed ID: 15655513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.
    Daniels S; Gitton X; Zhou W; Stricker K; Barton S
    J Womens Health (Larchmt); 2008 Apr; 17(3):423-37. PubMed ID: 18373490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen.
    Makarowski W; Zhao WW; Bevirt T; Recker DP
    Osteoarthritis Cartilage; 2002 Apr; 10(4):290-6. PubMed ID: 11950252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects.
    Goldstein JL; Kivitz AJ; Verburg KM; Recker DP; Palmer RC; Kent JD
    Aliment Pharmacol Ther; 2003 Jul; 18(1):125-32. PubMed ID: 12848634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis.
    Geusens P; Alten R; Rovensky J; Sloan VS; Krammer G; Kralidis G; Richardson P
    Int J Clin Pract; 2004 Nov; 58(11):1033-41. PubMed ID: 15605667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans.
    Hawkey CJ; Jones JI; Atherton CT; Skelly MM; Bebb JR; Fagerholm U; Jonzon B; Karlsson P; Bjarnason IT
    Gut; 2003 Nov; 52(11):1537-42. PubMed ID: 14570719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Schnitzer TJ; Beier J; Geusens P; Hasler P; Patel SK; Senftleber I; Gitton X; Moore A; Sloan VS; Poór G
    Arthritis Rheum; 2004 Aug; 51(4):549-57. PubMed ID: 15334426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
    Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
    Wittenberg RH; Schell E; Krehan G; Maeumbaed R; Runge H; Schlüter P; Fashola TO; Thurston HJ; Burger KJ; Trechsel U
    Arthritis Res Ther; 2006; 8(2):R35. PubMed ID: 16469112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.
    Van Hecken A; Schwartz JI; Depré M; De Lepeleire I; Dallob A; Tanaka W; Wynants K; Buntinx A; Arnout J; Wong PH; Ebel DL; Gertz BJ; De Schepper PJ
    J Clin Pharmacol; 2000 Oct; 40(10):1109-20. PubMed ID: 11028250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-effect comparisons of the CINOD AZD3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects.
    Wilder-Smith CH; Jonzon B; Fornstedt-Wallin B; Hedman A; Karlsson P
    Scand J Gastroenterol; 2006 Mar; 41(3):264-73. PubMed ID: 16497612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.
    Rordorf CM; Choi L; Marshall P; Mangold JB
    Clin Pharmacokinet; 2005; 44(12):1247-66. PubMed ID: 16372823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastroduodenal tolerability of highly specific cyclo-oxygenase-2 inhibitor.
    Hayllar J; Bjarnason I
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():30-2. PubMed ID: 9032580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
    Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
    Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.